Changeflow GovPing Government & Legislation DEA Notice Comment Period
Priority review Consultation Added Consultation

DEA Notice Comment Period

Favicon for www.regulations.gov Regulations.gov Proposed Rules
Detected March 19th, 2026
Email

Summary

The Drug Enforcement Administration (DEA) is providing a comment period for a notice, which closes on April 20, 2026. Interested parties are encouraged to submit their feedback through the Regulations.gov portal.

What changed

The Drug Enforcement Administration (DEA) has opened a comment period for a notice, with the deadline for submissions set for April 20, 2026. The notice is available for review and public comment on Regulations.gov under docket number DEA-2026-0430-0001.

Regulated entities, including drug manufacturers and pharmaceutical companies, should review the notice and submit any relevant comments by the April 20, 2026 deadline. Failure to submit comments by this date may result in the information not being considered by the agency. The submission process allows for individual or organizational comments, with options for anonymous submission. Attachments are permitted, subject to file size and type limitations.

What to do next

  1. Review DEA notice DEA-2026-0430-0001
  2. Submit comments via Regulations.gov by April 20, 2026

Source document (simplified)

Write a Comment

Commenter's Checklist
Public Comments on Federal Regulations

Comment *

5000

Attach Files

You can attach up to 20 files, but each file cannot exceed 10MB. Valid file types include: bmp, docx, gif, jpg, jpeg, pdf, png, pptx, rtf, sgml, tif, tiff, txt, wpd, xlsx, xml. Drop files here or Browse...

Email Address

Opt to receive email confirmation of submission and tracking number?
If you choose to identify as Anonymous, the option to receive an email confirmation will not be displayed. (We will never post the email address entered in the field above on Regulations.gov nor share it with anyone else.)

Tell us about yourself! I am... *

(Select an identity below)

An Individual

Yourself or another person whom
you represent with their consent

An Organization

A company, organization,
or government agency

Anonymous

A person who does not want their name
associated with the comment

Note: If you choose to identify as Anonymous, the option to enter your email address for submission confirmation is not available.

reCAPTCHA *

Solve with 2Captcha Do not submit personally identifiable information through this form. Any personally identifiable information (e.g., name, address, phone number) included in the comment form or in an attachment may be publicly disclosed in a docket or on the Internet (via Regulations.gov, a federal agency website, or a third-party, non-government website with access to publicly-disclosed data on Regulations.gov). By submitting a comment, you agree to the terms of participation and privacy notice.

Submit Comment

Please see the Privacy Notice and User Notice regarding comment submission.

Any information (e.g., personal or contact) you provide on this comment form or in an attachment may be publicly disclosed and searchable on the Internet and in a paper docket and will be provided to the Department or Agency issuing the notice. To view any additional information for submitting comments, such as anonymous or sensitive submissions, refer to the Privacy Notice and User Notice, the Federal Register notice on which you are commenting, and the Web site of the Department or Agency.

Classification

Agency
GSA
Compliance deadline
April 20th, 2026 (32 days)
Instrument
Consultation
Legal weight
Non-binding
Stage
Consultation
Change scope
Minor

Who this affects

Applies to
Drug manufacturers Pharmaceutical companies Healthcare providers
Geographic scope
National (US)

Taxonomy

Primary area
Healthcare
Operational domain
Compliance
Topics
Pharmaceuticals Public Health

Get Government & Legislation alerts

Weekly digest. AI-summarized, no noise.

Free. Unsubscribe anytime.

Get alerts for this source

We'll email you when Regulations.gov Proposed Rules publishes new changes.

Free. Unsubscribe anytime.